Extrapyramidal disorders due to the intake of antipsychotics

Abstract

Among the side effects of taking antipsychotics, the leading place is occupied by extrapyramidal syndromes (ES) - akathisia, acute and tardive dyskinesia, parkinsonism, syndrome of the "leaning tower of Pisa", "rabbit", acute neuroleptic syndrome. The concept of a neuroleptic threshold assumes the simultaneous development of an antipsychotic effect and the emergence of an extrapyramidal syndrome. It has been proven that most antipsychotics have a limited therapeutic dose corridor, and ES caused by antipsychotics, which reduces the quality of life, occurs in 50-60% of cases and is the main reason for stopping treatment with these drugs [19].

Keywords

Bekhterev neurology archive

References

[1] Арушанян Э.Б., Столяров Г.В. Хвостатое ядро и психопатология //Журн. невропатол. и психиатр. — 1977. — Вып. 2. - Т. 77. - С.284 - 290.

[2] Малин Д.И., Костицын Н.В. Клиника и терапия эндогенных психозов, осложненных злокачественным нейролептическим синдромом. — М., 1996.

[3] Мосолов С.Н. Основы психофармакологии. — М., 1996.

[4] Отеллин В.А., Арушанян Э.Б. Нигро-стрионигральная система. — М., 1989.

[5] Ayd F.G. // J. Am. Med. Assoc. — 1961. — Vol. 175. - P.1054 - 1060.

[6] Barnes T.R.E., Braude W.M. // Arc. of General Psychiatry. — 1985. — Vol. 42. — P.874 — 878.

[7] Bench C.J., Lammertsma A.A., Grasby P.M. et al. Time course of occupancy of striatal dopamine D2- receptors by the neuroleptic Ziprasidone determined by PET //Psychopharmacology in press. — 1995.

[8] Bilder R.M., Wu H., Bogerts B. et al. //Am. J. Psychiatry. — 1994. — Vol. 151. — P. 1437 — 1447.

[9] Bondarenko E.S., Malyshev Iu.I., Blagosklonov A.V. //Sov. Med. - 1991. - Vol. 12. - P.21 - 24.

[10] Brown R., Colter N., Corsellis J.A.N. et al. // Arc. General Psychiatry. — 1986. — Vol. 43. — P.36 — 42.

[11] Burt D.R., Greese I., Snyder S.H. //Science. — 1977. - Vol. 196. - P.326.

[12] Carlsson A. //Intern. Clin. Psychopharmacology. — 1995. - Vol. 10. — P.21 — 28.

[13] Casey D.A. // Psychopharmacology. — 1992. — Vol. 107. — P. 18 — 22.

[14] Casey D.E. //Drug-Induced Movement Disorders. — 1992. — P.21 — 40, Futura, Mount Kisko.

[15] Casey D.E. Paradoxical tardive dyskinesia //Disorders of Moverment in Psychiatry and Neurology. — 1992. — P.67 — 69. Dlackwell, Cambridge.

[16] Casey D.E. //Psychiatr. Clin. North. Am. — 1993. - Vol. 16. - P.589 - 6101.

[17] Casey D.E. //Acta Psych. Scand. Suppl. — 1994. — Vol. 380. - P. 14 - 20.

[18] Casey D.E. //Intern. Clin. Psychopharmacology. — 1995. - Vol. 10. — P.105 — 113.

[19] Casey D.E., Keepers G.A. //Psychopharmacology. - 1988, - P. 74 - 93.

[20] Cools A.R., Rossum J.M. //Life Sci. — 1980. — Vol. 27. - P. 1237.

[21] Crane G.E. //Arch. Neurol. - 1972. - Vol. 27. - P.426 - 430.

[22] Creen M.F, Satz P., Smith C., Nelson L.D. // J. Abnormal Psychology. — 1989. — Vol. 98. — P.57 — 61.

[23] Crow T.J., Ball J., Bloom S.R. et al. //Arch. General Psychiatry. — 1989. — Vol. 46. — P. 1145 — 1150.

[24] Crow T.J., Colter N., Frith C.D., Johnstone E.C., Owens D.G.C. //Psychiarty Research. — 1989. — Vol. 29. - P.247 - 253.

[25] Deniker P. Introduction of neuroleptic chemotherapy into psychiatry. In: Discoveries in Biological Psychiatry. — 1984. — P. 155 — 164.

[26] Di Chiara G., Morelli M., Acquas E., Carboni E. Functions of dopamine in the extrapyramidal and limbic systems. Clues for the mechanism of drug actions. University of Cagliari, Department of Toxicology, Italy. Arzneimittelforschung, 1992. — Vol. 42. — P.231 - 237.

[27] Dilsaver S.C. Antipsychotic agents: a review. Harris County Psychiatric Center, University of Texas Medical School, Houston //Am. Fam. Physician. - 1993. - Vol. 47. - P. 199 - 204.

[28] Fabre L., Slotnick V., Jones V., Murray G., Malic J. ICI 204, 636, a novel atypical antipsychotic: early indication for safwrty and efficacy in man. Abstracts of the 17th Congress of the Collegium //Intern. neuropsychopharmacologicum. — Kyoto, 1990. — Vol. II. - P.223.

[29] Farde L. // Psychopharmacology. — 1992. — Vol. 107. - P.23 - 29.

[30] Gerlach J., Reisby N., Randrup A. //Psychopharmacology. — 1974. — Vol. 34. — P.21 — 35.

[31] Gerlach J., Casey D.E., Kistrup K. et al. //Neurology and Neurobiology. — 1988. — Vol. 42. — P. 1 — 4.

[32] Gerlach J. New antipsychotics: classification, efficacy and adverse effects. — Schizofr-Buli, 1991. — Vol. 17. - P.289 - 309.

[33] Gerlach J., Hansen L. Clozapine and D1/D2 antagonism in extrapyramidal functions. St. Hans Hospital, Department P, Roskilde, Denmark. Br. //J. Psych. — 1992. — P.34 — 37.

[34] Gerlach J., Peacock L. // Intern. Clin. Psychopharmacology. — 1995. — Vol. 10. — P. 39 — 48.

[35] Hartman D.S., Civelli O. //Ann. Med. — 1996. - Vol. 28. - P.211 - 219.

[36] Harvey I., Ron M.A., Du Boulay S., Wicks D., Lewis S.W., Murray R.M. //Psychol. Med. — 1993. — Vol. 23. - P.591 - 604.

[37] Hirsch S.R. //Neuropsychopharmacology. - 1994. — Vol. 10. - P.371.

[38] Hoberg O.J., Fensbo C., Remvig J., Lingjaerde O., Sloth - Nielsen M., Salvesen I. //Acta Psychiatr. Scand. - 1993. - Vol. 88. - P.395 - 402.

[39] Holemans S., Javoy F., Agid Y., Laterre E.C., Maloteaux J.M. //Brain. Res. — 1991. — Vol. 565. — P.154 - 157.

[40] Inagaki T., Ishino H., Iijima M., Seno H., Kikumoto O., Yoshinaga J., Matsuura H., Tachiyama Y. //No-To-Shinkei. — 1996. - Vol. 48. - P. 1037 - 1045.

[41] Jaynes J. The origins of Consciousness in the Breakdown of the Bicameral Mind. — Houghton Mifflin, Boston, 1990.

[42] Johnstone E.C., Crow T.J., Husband J., Kreel L. //Lancet. - 1976. - P.924 - 926.

[43] Johnstone E.C., Owens D.G., Bydder et al. //Psychol. Med. - 1989. - Vol. 19. - P.91 - 103.

[44] Kapur S., Remington G., Zipursky R.B., Wilson A.A. //Life Sci. - 1995. - Vol. 57. - P. 103 - 107.

[45] Kebabian J. W., Calne D.B. //Nature. - 1979. - Vol. 277. - P.93.

[46] Keepers G.A., Clappison V.J., Casey D.E. // Arch. Gen. Psychiatry. — 1983. — Vol. 40. — P. 1113 — 1117.

[47] Klawans H.L., Weiner W.J. //Progr. Neurobiol. — 1976. - Vol. 6. - P.49.

[48] Levander T., Westerberght S., Morrison D. //Acta Psych. Scand. Suppl — 1990. — Vol. 358. — P.92 - 98.

[49] Levinson D.F., Simpson G.M., Singht H. et al. //Arch. Gen. Psych. - 1990. - Vol. 47. - P.761 - 768.

[50] Lieberman J.A., Salts B.L., Johns C.A., Pollack S., Borenstein M., Kane J. //British J. Psych. — 1991. - Vol. 158. - P.503 - 510.

[51] Marsden C.D., Tarsy D., Baldessarini R.J. In: Psychiatric Aspects of Neurologic Diseases. — 1975. — 219. N.-Y.

[52] Martin P.T., Grebb J.A., Johns C.A. et al. Efficacy and safety of sertindole in two boudle-blind, placebo- controlled trials of schizophrenic pacients. Poster presented at Biennial Winter Workshop on Schizophrenia Research. — Les Diablets, Switzerland, 1994.

[53] McHugh D., Coffin V. //Am. J. Psych. — 1994. — Vol. 202. - P. 133 - 134.

[54] Meltzer H.Y., Gudelsky G.A. //Arzneimittelforschung, 1992. — Vol. 42. - P.268 - 272.

[55] Migler B.M., Warawa E.J., Malick J.B. // Psychopharmacology. — 1993. — Vol. 112. — P.299 - 307.

[56] Moor N.A., Calligaro D.O., Wong D.T., Bymaster F., Tye N.C. //Psychopharmacology. — 1993. — Vol. 112. — P.299 — 307.

[57] Moor N.A., Tupper D.E., Hotten T.M. //Olanzapint. Drugs of the Future 19. — 1994. — P.l14 — 117.

[58] Muller P., Seemen P. //Life Sci. — 1977, - Vol. 21. - P.1751.

[59] Nasrallah Н.А. //Comprehensive Psychiatry. — 1985. - Vol. 26. - P.273 - 282.

[60] Nyquist O.G. //Tidsskr. Nor. Laegeforen. — 1996. — Vol. 116. - P.2879 - 2882.

[61] Owens D.G. //Drugs. — 1996. — Vol. 51. — P.895 - 930.

[62] Pakkenberg B. //Brit. J. Psychiatry. — 1987. — Vol. 151. - P.744 - 752.

[63] Peacock L., Solgaard T., Lublin H., Gerlach J. //Psychopharmacology. — 1995.

[64] Pearlson G.D., Kim W.S., Kubos K.L. et al. //Arch. Gen. Psychiatry. — 1989. — Vol. 46. — P.690 — 697.

[65] Saller G.F., Salama A.I. //Psychopharmacology. — 1993. — Vol. 112. - P.285 - 292.

[66] Schwartz J.C., Griffon N.J., Diaz et al. //Intern. Clin. Psychopharmacology. — 1995. — Vol. 10. — P. 15 — 20.

[67] Seeman F. //Pharmacology Review. — 1980. — Vol. 32. - P.229.

[68] Seeman 1975b 1976, Greese 1976, TI: Molecular attributes of dopamine receptors: new potential for antipsychotic drug development.

[69] Smith J., Baldessarini R. //Arch. Gen. Psychiat. — 1980. - Vol.37. - P. 1368 - 1375.

[70] Stevens R.F. //Eur. J. Cancer. — 1991. — Vol. 27. — P.20 - 22.

[71] Swett C. //Am. J. Psychiat. — 1975. — Vol. 132. — P.532 - 534.

[72] Szegedi A., Wiesner J., Hillert A., Hammes E., Wetzel H., Benkert O. //Psychopharmacology. — 1993. - Vol. 26. - P. 197.

[73] Tamminga C.A. A new antipsychotic drug, sertindole: clinical effects and perspectives. Presented at a symposium on drug treatment of schizophrenia: from molecular biology to patients’ subjective experience. — 1995. — June 9 — 10. Lundbeck, Copenhagen.

[74] Tartaglione S., Iorio N., Pontarelli E. //Minerva. Psichiatr. - 1992. - Vol. 33. - P.45 - 50.

[75] Tran P.V., Beaslev C.M., Toffelsen G.D., Sanger T., Satterlee W.G. Clinical efficacy and safety of olanzapine, new atypical antipsychotic agent. Poster presented at the Annual Meeting of the American Psychiatric Association. — Philadelphia, 1994.

[76] Vernon G.M. // J. Neurosci. Nurs. — 1991. — Vol. 23. - P.183 - 187.

[77] Villencuve A. //Can. Psych. Ass. J — 1972. — Vol. 17. - P.69 - 72.

[78] Weller M., Kornhuber J. //Fortschr. Neurol. Psychiatr. - 1993. - Vol. 61. - P.217 - 222.

[79] Wetzel H., Szegedi A., Hain C., Wiesner J., Schlegel S., Benkert O. //Psychopharmacology. — 1995. — Vol. 119. - P.231 - 238.

[80] Wienberger D.R., Torrey E.F., Neophytides A.N., Wyatt R.T. //Arch. Gen. Psych. — 1979. — Vol. 36. — P.735 - 739.

[81] Zipursky R.B., Lim K.O., Sullivan E.V. et al. //Arch. Gen. Psych. - 1992. - Vol. 49. - P. 195 - 205.

[82] Zorn S.H., Morrone J.M., Seeger T.F. et al. //Society of Neuroscience Abstract. — 1993. — Vol. 19. - P.599.

RIGHTS & PERMISSIONS

Zalyalova Z.A., Bogdanov E.I.